Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.

  • December 17, 2025

  • 4 min

Share

Original Source(s)

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

  • December 17, 2025

Related Content

Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management

Two Dana-Farber Hematologists Receive Top Honors From the American Society of Hematology

The American Society of Hematology is recognizing 11 distinguished hematologists with its most prestigious awards and named lectures, honoring transformative contributions that have advanced research, patient care, and education in blood disorders. Two of this year’s honorees are from Dana-Farber Cancer Institute: Benjamin L. Ebert, MD, PhD, and Scott A. Armstrong, MD, PhD.

  • by

  • June 23, 2026

  • 4 min
Beyond classical boundaries: rethinking ICU access in acute leukemia